Additionally, inhibitory effects of triptolide at XPB ATPase specific targeted site on CDK12 and CDK13 (TFIIH subunit XPB) is under phase-I clinical trial in combination with paclitaxel for advanced stage solid tumor and HIV; and for effective treatment of pancreatic cancer, triptolide is under phase phase-II clinical trial [40]. The gene discussed is ERCC3; the disease is pancreatic neoplasm.